MEP27508A - Derivati n-((3-okso 2,3-dihidro-1-n-izoindol-1-il)acetil) gvanidina kao ihibitori nhe-1, za liječenje infrakta i angine pektoris - Google Patents

Derivati n-((3-okso 2,3-dihidro-1-n-izoindol-1-il)acetil) gvanidina kao ihibitori nhe-1, za liječenje infrakta i angine pektoris

Info

Publication number
MEP27508A
MEP27508A MEP27508A MEP27508A ME P27508 A MEP27508 A ME P27508A ME P27508 A MEP27508 A ME P27508A ME P27508 A MEP27508 A ME P27508A
Authority
ME
Montenegro
Prior art keywords
infarction
treatment
angina pectoris
oxo2
nhe
Prior art date
Application number
Other languages
Bosnian (bs)
English (en)
Inventor
Heinz-Werner Kleemann
Armin Hofmeister
Jean-Christophe Carry
Serge Mignani
Antony Bigot
Baptiste Ronan
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MEP27508A publication Critical patent/MEP27508A/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP27508 2002-06-03 2003-05-20 Derivati n-((3-okso 2,3-dihidro-1-n-izoindol-1-il)acetil) gvanidina kao ihibitori nhe-1, za liječenje infrakta i angine pektoris MEP27508A (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0206783A FR2840302B1 (fr) 2002-06-03 2002-06-03 Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
PCT/EP2003/005279 WO2003101450A1 (en) 2002-06-03 2003-05-20 N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris

Publications (1)

Publication Number Publication Date
MEP27508A true MEP27508A (hr) 2010-06-10

Family

ID=29558914

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP27508 MEP27508A (hr) 2002-06-03 2003-05-20 Derivati n-((3-okso 2,3-dihidro-1-n-izoindol-1-il)acetil) gvanidina kao ihibitori nhe-1, za liječenje infrakta i angine pektoris

Country Status (42)

Country Link
US (2) US7078428B2 (hr)
EP (1) EP1528923B1 (hr)
JP (1) JP4634793B2 (hr)
KR (1) KR101149771B1 (hr)
CN (1) CN1290833C (hr)
AR (1) AR039927A1 (hr)
AT (1) ATE324889T1 (hr)
AU (1) AU2003240677B2 (hr)
BR (1) BR0311556A (hr)
CA (1) CA2488373C (hr)
CY (1) CY1105115T1 (hr)
DE (1) DE60305042T2 (hr)
DK (1) DK1528923T3 (hr)
EC (1) ECSP045472A (hr)
EG (1) EG24784A (hr)
ES (1) ES2261939T3 (hr)
FR (1) FR2840302B1 (hr)
HK (1) HK1076383A1 (hr)
HN (1) HN2003000162A (hr)
HR (1) HRP20041151B1 (hr)
IL (1) IL165520A (hr)
JO (1) JO2357B1 (hr)
MA (1) MA27308A1 (hr)
ME (1) MEP27508A (hr)
MX (1) MXPA04011931A (hr)
MY (1) MY142502A (hr)
NO (1) NO329224B1 (hr)
NZ (1) NZ536953A (hr)
OA (1) OA12864A (hr)
PA (1) PA8574701A1 (hr)
PE (1) PE20040531A1 (hr)
PL (1) PL372188A1 (hr)
PT (1) PT1528923E (hr)
RS (1) RS51636B (hr)
RU (1) RU2318809C2 (hr)
SI (1) SI1528923T1 (hr)
TN (1) TNSN04237A1 (hr)
TW (1) TWI286545B (hr)
UA (1) UA81118C2 (hr)
UY (1) UY27835A1 (hr)
WO (1) WO2003101450A1 (hr)
ZA (1) ZA200409094B (hr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10356717A1 (de) * 2003-12-02 2005-07-07 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von (3-Oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-Derivaten
US7531569B2 (en) 2003-12-02 2009-05-12 Sanofi-Aventis Deutschland Gmbh Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives
KR100518184B1 (ko) * 2003-12-27 2005-10-04 한국화학연구원 퓨란카보닐구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
TW200812962A (en) * 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
GB0811643D0 (en) * 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
TW201321371A (zh) 2011-10-14 2013-06-01 Incyte Corp 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物
CN103193794B (zh) * 2013-04-12 2016-04-06 中国药科大学 一种异吲哚酮并异噁唑类稠环化合物及其合成方法
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
CN106316922B (zh) * 2016-08-17 2019-02-01 华东师范大学 一种含c-3全取代氧化吲哚衍生物及其合成方法和应用
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN110664803B (zh) * 2019-09-19 2023-08-29 中山大学 异吲哚酮类化合物在制备防治溶骨性疾病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE157351T1 (de) * 1993-02-20 1997-09-15 Hoechst Ag Substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament, als inhibitoren des zellulären na+/h+-austauschs oder als diagnostikum sowie sie enthaltendes medikament
FR2735166B1 (fr) * 1995-06-08 1997-08-29 Aerospatiale Procede de fabrication d'un panneau ou analogue a proprietes structurale et acoustique et panneau ainsi obtenu
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
DE19738604A1 (de) * 1997-09-04 1999-03-11 Hoechst Marion Roussel De Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verminderung der Giftigkeit cardiotoxischer Stoffe
AU739403B2 (en) * 1998-02-27 2001-10-11 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia
DE19859727A1 (de) * 1998-12-23 2000-06-29 Aventis Pharma Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
PL357765A1 (en) * 2000-04-28 2004-07-26 Pfizer Products Inc. Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
DE10046993A1 (de) * 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
EP1385823B1 (en) * 2001-04-09 2006-12-13 Chiron Corporation Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists

Also Published As

Publication number Publication date
UY27835A1 (es) 2003-12-31
PE20040531A1 (es) 2004-09-27
KR101149771B1 (ko) 2012-06-08
FR2840302B1 (fr) 2004-07-16
OA12864A (en) 2006-09-15
JO2357B1 (en) 2006-12-12
HK1076383A1 (en) 2006-01-20
PL372188A1 (en) 2005-07-11
US7078428B2 (en) 2006-07-18
HN2003000162A (es) 2004-05-05
RS104804A (en) 2006-12-15
JP2005533034A (ja) 2005-11-04
TNSN04237A1 (en) 2007-03-12
ZA200409094B (en) 2005-08-31
HRP20041151B1 (hr) 2013-06-30
ECSP045472A (es) 2005-01-28
DE60305042D1 (de) 2006-06-08
RS51636B (en) 2011-08-31
MXPA04011931A (es) 2005-03-31
CA2488373C (en) 2012-07-17
IL165520A (en) 2009-12-24
ATE324889T1 (de) 2006-06-15
CA2488373A1 (en) 2003-12-11
KR20050010855A (ko) 2005-01-28
AR039927A1 (es) 2005-03-09
JP4634793B2 (ja) 2011-02-16
CN1290833C (zh) 2006-12-20
MA27308A1 (fr) 2005-05-02
US20060148880A1 (en) 2006-07-06
SI1528923T1 (sl) 2006-08-31
WO2003101450A1 (en) 2003-12-11
DE60305042T2 (de) 2007-05-24
US20040048916A1 (en) 2004-03-11
RU2318809C2 (ru) 2008-03-10
TWI286545B (en) 2007-09-11
NO20045660L (no) 2004-12-27
BR0311556A (pt) 2005-04-12
PT1528923E (pt) 2006-08-31
EP1528923A1 (en) 2005-05-11
HRP20041151A2 (en) 2005-06-30
NO329224B1 (no) 2010-09-20
CN1658869A (zh) 2005-08-24
TW200404780A (en) 2004-04-01
RU2004138789A (ru) 2005-06-27
CY1105115T1 (el) 2010-03-03
AU2003240677B2 (en) 2008-07-17
ES2261939T3 (es) 2006-11-16
DK1528923T3 (da) 2006-09-04
MY142502A (en) 2010-11-30
AU2003240677A1 (en) 2003-12-19
US7589117B2 (en) 2009-09-15
UA81118C2 (en) 2007-12-10
EP1528923B1 (en) 2006-05-03
IL165520A0 (en) 2006-01-15
EG24784A (en) 2010-09-01
NZ536953A (en) 2007-10-26
FR2840302A1 (fr) 2003-12-05
PA8574701A1 (es) 2004-05-07

Similar Documents

Publication Publication Date Title
MEP27508A (hr) Derivati n-((3-okso 2,3-dihidro-1-n-izoindol-1-il)acetil) gvanidina kao ihibitori nhe-1, za liječenje infrakta i angine pektoris
Goel et al. Benzamide-based thiolcarbamates: a new class of HIV-1 NCp7 inhibitors
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
KR950704304A (ko) 이환식 헤테로환 함유 술폰아미드 및 술폰산 에스테르 유도체(bicyclic heterocyclic sulfonamide and sulfonic ester derivatives)
NO950009L (no) Heterocykliske forbindelser som farmasöytika
BR0014641A (pt) Derivados de sulfonamida farmaceuticamente ativa, uso de um derivado de sulfonamida, uso de sulfonamidas, composto farmacêutico contendo pelo menos um derivado de sulfonamida e processo para preparação de um derivado de sulfonamida
HUP0202758A2 (hu) Izomer kondenzált pirrolokarbazolok és izoindolok és intermedierjeik, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HRP20050830A2 (en) Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
HUP0202248A2 (hu) Gyulladásgátló szerekként alkalmazható vegyületek
DE60232065D1 (de) Indol-, azaindol- und verwandte heterozyklische amidopiperazin-derivate
BR0200982A (pt) Compostos do ácido alfa-amino sulfonila, um processo para sua preparação e composições farmacêuticas compreendendo os mesmos
HUP0301834A2 (hu) Heterociklusos dihidropirimidin-származékok alkalmazása káliumcsatorna inhibitor hatású gyógyszerkészítmények elżállítására, valamint új származékok és az ezeket tartalmazó gyógyszerkészítmények
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
EA200000792A2 (ru) Новые пиридиновые соединения, способ их получения и содержащие их фармацевтические композиции
Ma et al. Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors
EP1500648A4 (en) NEW PIPERIDINE DERIVATIVES
BRPI0810821A8 (pt) Derivados de anéis aromáticos de seis membros contendo nitrogênio e produtos farmacêuticos contendo os mesmos
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
HUP0000729A2 (hu) Új amidszármazékok és ezeket tartalmazó gyógyszerkészítmények
HRP20041078B1 (hr) Pentafluorsulfanil-benzoilgvanidini, postupak za njihovu pripravu, njihova upotreba kao lijeka ili dijagnostika, kao i lijek koji ih sadrži
RU94046369A (ru) Новые стероиды на основе прегнана и фармацевтические композиции, их содержащие
BRPI0516704A (pt) composto, processo para a preparação de um composto, processo para produzir uma composição farmacêutica, composição farmacêutica, uso de um composto e uso de uma composição farmacêutica
EA200700818A1 (ru) Производные 1,2,4-триазолиламиноарил(гетероарил)сульфонамидов
CN105237459B (zh) 一步合成2-磺酰基取代异吲哚啉-1-酮类化合物的方法
EA200001248A1 (ru) Новые линейные и циклические производные мочевины, способ их получения и их содержащие фармацевтические композиции